Phaseline

Targets › HPRT1

HPRT1 (Hypoxanthine-guanine phosphoribosyltransferase): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Neurology.

Converts guanine to guanosine monophosphate, and hypoxanthine to inosine monophosphate. Transfers the 5-phosphoribosyl group from 5-phosphoribosylpyrophosphate onto the purine. (UniProt, P00492)

Open in Phaseline: the race on HPRT1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Fujita Health UniversityInosine
Purine nucleoside precursor for uric acid synthesis
HPRT1Phase 1Parkinson's Disease (PD)–

Conditions

Parkinson's Disease (PD) (1)

Modalities

small molecule (1)

Companies

Fujita Health University (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.